Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis

Fig. 2

Maximum dose and frequency of infliximab administered through 18 months* (n = 4502). *Restricted to patients with a consistent dose for all 3 infusions, throughout the induction period (week 0, 2, 6), at starting doses of 200, 300, or 400 mg, representing 87% of all 5174 patient in the infliximab cohort. All patients were assumed to be starting at a dose of 3 mg/kg, every 8 weeks. In this analysis, only a single dose and frequency increase was required, unlike in the main analysis where two consecutive infusions were required to meet the dose escalation definition. **Infusion interval for q6w infusion ranges from 36 to 48 days, inclusive (42 ± 6 days). ***Infusion interval for q4w infusion ranges from 22 to 34 days, inclusive (28 ± 6 days)

Back to article page